CoChat
Sign Up
Cited by 5Mesenchymal stem cell researchCancer Cells and MetastasisBacterial Cancer Therapy

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The role of mesenchymal stem cells in oncology and regenerative medicine

Maliha, Khan, Syeda Ezze Rukhshan, Adil, Amanda L, Olson·2017·Future Oncology
DOI 10.2217/fon-2016-0264
Open this paper in CoChat — free account

Abstract

Mesenchymal stem cells (MSCs) have long been used as therapeutic agents in disease affecting various organ systems. However, MSCs are fast emerging as promising anticancer agents which have the potential to treat a number of different cancer types, including glioblastoma and metastatic breast, ovarian and hepatic carcinoma. The ability of MSC to migrate directly into the tumor microenvironment and to produce IFN-α and -β makes this possible. However, the possibility of MSC undergoing either malignant transformation or transformation into protumorigenic fibroblasts currently limits their role in clinical use. It is hoped that future research can overcome these limitations and facilitate the use of MSC clinically.

Overview

Integrity signals

Registry

Crossref · 10.2217/fon-2016-0264

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 92

  1. 10.1126/science.284.5411.143 · DOI · Paper page
  2. 10.1182/blood-2007-02-069716 · DOI
  3. 10.1002/jcp.20959 · DOI
  4. 10.1182/blood-2004-09-3696 · DOI
  5. 10.1016/S0003-4975(02)03517-8 · DOI
  6. 10.1016/j.stem.2012.05.015 · DOI · Paper page
  7. 10.1080/14653240500319234 · DOI
  8. 10.1002/stem.269 · DOI
  9. 10.1016/j.ijcard.2005.07.036 · DOI
  10. 10.1002/stem.643 · DOI
  11. 10.4252/wjsc.v7.i2.368 · DOI
  12. Gatti S , BrunoS, DeregibusMCet al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant.15, gfr015 (2011).
  13. 10.1002/stem.430 · DOI
  14. 10.1111/cei.12056 · DOI
  15. 10.1016/j.cgh.2013.06.021 · DOI
  16. 10.1007/s12272-012-0202-z · DOI
  17. 10.1002/jgm.2823 · DOI
  18. 10.1056/NEJMoa020177 · DOI · Paper page
  19. 10.1158/1535-7163.MCT-05-0334 · DOI · Paper page
  20. Studeny M , MariniFC, ChamplinREet al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res.62, 3603–3608 (2002).
  21. 10.1634/stemcells.2007-0197 · DOI
  22. Karp JM , TeoGS. Mesenchymal stem cell homing: the devil is in the details. Stem Cell4(3), 206–216 (2009).
  23. 10.1073/pnas.0507158102 · DOI
  24. 10.1182/blood-2007-07-103697 · DOI · Paper page
  25. 10.1002/jcb.20219 · DOI
  26. 10.1080/10245330290028588 · DOI
  27. Lowe JB . Glycosyltransferases and glycan structures contributing to the adhesive activities of L-, E- and P-selectin counter-receptors. Biochem. Soc. Symp. (69), 33–45 (2002).
  28. 10.1182/blood.V95.11.3289 · DOI
  29. 10.1016/j.yjmcc.2008.03.010 · DOI
  30. 10.3324/haematol.10475 · DOI
  31. 10.1182/blood-2007-12-128702 · DOI
  32. 10.1074/jbc.270.49.29439 · DOI
  33. 10.1634/stemcells.2005-0271 · DOI
  34. 10.1096/fj.06-6558com · DOI
  35. 10.1196/annals.1378.043 · DOI
  36. 10.1182/blood-2004-09-3507 · DOI
  37. 10.1182/blood-2004-02-0526 · DOI
  38. 10.1111/j.1432-2277.2011.01328.x · DOI
  39. 10.4049/jimmunol.180.4.2581 · DOI
  40. 10.1016/j.carrev.2005.10.008 · DOI
  41. 10.1634/stemcells.2007-0022 · DOI
  42. 10.1038/sj.leu.2402763 · DOI
  43. 10.1089/jir.2006.0037 · DOI
  44. 10.1080/14653240600855905 · DOI · Paper page
  45. Zanjani ED , Almeida-PoradaG, LivingstonAG, FlakeAW, OgawaM. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp. Hematol.26, 353–360 (1998).
  46. 10.1387/ijdb.072352ns · DOI
  47. 10.1038/sj.thj.6200232 · DOI
  48. 10.1038/sj.bmt.1703650 · DOI
  49. 10.1177/096368979500400409 · DOI
  50. 10.1089/107632701300062859 · DOI · Paper page
  51. 10.1634/stemcells.2005-0342 · DOI · Paper page
  52. 10.1073/pnas.132252399 · DOI · Paper page
  53. 10.1177/147323001204000132 · DOI
  54. 10.1089/10430349950018157 · DOI
  55. 10.1093/jnci/djh299 · DOI
  56. 10.1128/JVI.78.3.1219-1229.2004 · DOI
  57. 10.1006/mthe.2002.0585 · DOI
  58. 10.1196/annals.1392.000 · DOI
  59. Stender S , MurphyM, O’BrienTet al. Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur. Cell Mater.13(93–99), 99 (2007).
  60. 10.1016/j.canlet.2009.08.031 · DOI
  61. 10.1073/pnas.0806647106 · DOI
  62. 10.1634/stemcells.2008-0084 · DOI
  63. 10.1002/jcp.21200 · DOI · Paper page
  64. 10.1093/jnci/83.2.105 · DOI
  65. Kubo T , SugitaT, ShimoseS, NittaY, IkutaY, MurakamiT. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int. J. Oncol.18(1), 121–126 (2001).
  66. 10.1002/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I · DOI
  67. Wadler S , SchwartzEL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res.50(12), 3473–3486 (1990).
  68. 10.1002/ijc.2910570115 · DOI
  69. 10.1001/jama.1991.03470100067035 · DOI
  70. 10.1016/S0959-8049(05)80055-3 · DOI
  71. 10.1038/gt.2010.170 · DOI · Paper page
  72. Ueno T , ToiM, SajiHet al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res.6(8), 3282–3289 (2000).
  73. 10.1182/blood-2008-10-187237 · DOI
  74. 10.1038/nature06188 · DOI · Paper page
  75. 10.1089/hum.2007.034 · DOI
  76. 10.1038/sj.mt.6300300 · DOI
  77. 10.1634/stemcells.21-4-389 · DOI
  78. 10.1126/science.270.5238.908.a · DOI · Paper page
  79. 10.1182/blood.V87.9.3877.bloodjournal8793877 · DOI
  80. 10.1007/s13277-015-3277-6 · DOI
  81. 10.1038/sj.cdd.4401872 · DOI
  82. 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S · DOI
  83. 10.1038/74710 · DOI
  84. Ehtesham M , KabosP, KabosovaA, NeumanT, BlackKL, JohnSY. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res.62(20), 5657–5663 (2002).
  85. Ehtesham M , KabosP, GutierrezMAet al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res.62(24), 7170–7174 (2002).
  86. 10.1038/nrn1829 · DOI
  87. 10.1126/science.287.5457.1442 · DOI
  88. 10.1111/j.1349-7006.2005.00032.x · DOI
  89. 10.1158/0008-5472.CAN-04-1874 · DOI
  90. 10.1016/j.canlet.2009.08.028 · DOI
  91. 10.1158/0008-5472.CAN-08-0451 · DOI
  92. 10.1371/journal.pone.0004992 · DOI · Paper page

Cited by

Sorted by citations

  • Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?

    Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252

    “In the pro-inflammatory tumor microenvironment (TME) occurs the expression of a plethora of chemokines and cytokines, namely VEGF, FGF, PDGF, CCL5 and IL-8, that induce the migration of MSCs towards the tumor in an orchestrated manner by creating a chemokine concentration gradient [101].”

See all 5

Metadata

Authors
Maliha, K., Syeda Ezze Rukhshan, A., & Amanda L, O.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
  • Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Venue
Future Oncology
Publisher
Informa UK Limited
Published
2016-12-02
Volume
13
Issue
9
Pages
821-831
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
DOI
10.2217/fon-2016-0264
OpenAlex
W2557959975
Cited by
5
References
9
Citations by year
2024: 1 · 2023: 1 · 2021: 1 · 2020: 2
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Locations
  • Future Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
mesenchymal stem cells, cancer therapy, tumor microenvironment, malignant transformation, glioblastoma, metastatic breast cancer, ovarian cancer, hepatocellular carcinoma, regenerative medicine
MeSH terms
Animals, Cell Movement, Genetic Vectors, Humans, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Transduction, Genetic, Genetic Therapy, Cytokines, Transgenes, Regenerative Medicine, Mesenchymal Stem Cell Transplantation, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review